Re: Adjuvant Pembrolizumab After Nephrectomy in Renal-cell Carcinoma

Eur Urol. 2022 Mar;81(3):317-318. doi: 10.1016/j.eururo.2021.11.026. Epub 2021 Dec 9.

Authors

Diana E Magee¹, Alexander Kutikov²

Affiliations

¹ Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.
² Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA. Electronic address: [email protected].

PMID: 34895924
DOI: 10.1016/j.eururo.2021.11.026

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / surgery
Female
Humans
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / pathology
Kidney Neoplasms* / surgery
Male
Nephrectomy

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab